Nivolumab with chemotherapy improves response, survival in AML study patients
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled reaction rates and improved overall success in patients with acute myeloid leukemia (AML), according to preliminary findings by researchers at The University of Texas MD Anderson Cancer Center.
Related Posts:CTCA at Western Regional Medical Center advances combinationImmunotherapy with live bacterium improves response rate in…Adjuvant chemotherapy improves overall survival in patients…Drug shows surprising efficacy as therapy for chronic…Experts propose new staging for HPV-related oropharyngeal…The post Nivolumab with chemotherapy improves response, survival in AML study patients appeared first on My Irritable Bowel Syndrome Story.
Source: My Irritable Bowel Syndrome Story - Category: Gastroenterology Authors: Ken Tags: IBS News Source Type: blogs
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Immunotherapy | Irritable Bowel Syndrome | Leukemia | Oropharyngeal Cancer | Study | Texas University